Key Points
- Moderna shares jumped more than 16% following the publication of Phase 3 data in the New England Journal of Medicine showing its mRNA flu vaccine (mRNA-1010) surpassed a licensed standard-dose flu shot in adults aged 50 and above.
- Wall Street analysts from Evercore ISI, Goldman Sachs, and Piper Sandler increased their price targets on Moderna after the company’s Q1 2026 earnings report, with targets reaching $50, $49, and a new Buy rating respectively.
- Brief market attention focused on Moderna’s early-stage hantavirus development program after a cluster of cases emerged on a cruise ship, though analysts dismiss any significant commercial potential from this program.
- Regulatory approval for mRNA-1010 is pending, with the FDA’s PDUFA target date scheduled for August 5, while submissions in Europe, Canada, and Australia remain under evaluation.
- Competitors Pfizer and BioNTech discontinued recruitment for a significant U.S. COVID vaccine study in the 50-64 age group due to insufficient enrollment numbers.
Shares of Moderna were changing hands near $56 during Thursday’s session, reflecting a gain exceeding 16%, driven by impressive clinical trial outcomes, multiple analyst upgrades, and brief speculation around hantavirus developments.
The primary catalyst was clear-cut: the publication of Phase 3 clinical trial data for Moderna’s mRNA-based seasonal influenza vaccine, mRNA-1010, in the prestigious New England Journal of Medicine. The results demonstrated that the vaccine achieved its predefined superiority endpoint when compared against a commercially available standard-dose seasonal influenza vaccine in participants 50 years of age and older.
This represents a significant achievement. Demonstrating superiority over an already-approved vaccine in a peer-reviewed medical journal provides substantial support for Moderna’s regulatory submission as the company approaches a critical FDA milestone.
The regulatory timeline shows the FDA has designated August 5 as the PDUFA target date for mRNA-1010. Additionally, regulatory authorities in Europe, Canada, and Australia are currently reviewing applications, positioning this as a potentially global product launch if regulatory clearances are granted.
Wall Street analysts contributed momentum to the rally. Evercore ISI increased its price objective from $35 to $50. Goldman Sachs elevated its target from $43 to $49. Piper Sandler established coverage with a Buy recommendation. These adjustments followed Moderna’s first-quarter 2026 financial results.
Hantavirus Developments Created Brief Market Buzz
A hantavirus cluster involving travelers aboard a Dutch-registered cruise vessel traveling from Argentina to Cabo Verde temporarily boosted Moderna shares during early trading hours. Eight individuals were affected, with three fatalities reported, and five cases confirmed as Andes virus — the sole hantavirus variant documented to enable limited person-to-person transmission.
The World Health Organization assessed the public health threat as minimal. During a Thursday briefing, Dr. Maria Van Kerkhove stated unequivocally: “This is not the start of a COVID pandemic.”
Evercore ISI highlighted a Moderna partnership with Korea University focused on hantavirus research initiated in 2023, but expressed clear skepticism about commercial prospects. The firm stated it identifies “no meaningful revenue opportunity” stemming from the outbreak-related headlines and emphasized that Moderna’s hantavirus candidate “remains very early stage.” The stock, analysts observed, “tends to trade on outbreak headlines well beyond the underlying commercial implications.”
In summary: while hantavirus developments generated temporary interest, the influenza vaccine results and analyst rating changes provided the genuine market momentum.
Cruise Industry Shares Experienced Headwinds
Cruise operator equities faced selling pressure following the hantavirus reports. Royal Caribbean declined approximately 2% during the session, while Carnival experienced a comparable decrease. Norwegian Cruise Line Holdings dropped nearly 3%. Viking Holdings and Lindblad Expeditions each retreated around 2.5%.
Regarding competitive dynamics, Pfizer and BioNTech terminated patient recruitment for a substantial U.S. COVID vaccine clinical trial focused on adults between 50 and 64 years old, attributing the decision to inadequate enrollment. This development could potentially strengthen Moderna’s competitive standing in the next-generation vaccine marketplace.
Broader equity markets provided a favorable backdrop, with the S&P 500 advancing 0.71%, the Dow gaining 0.21%, and the Nasdaq climbing 1.16%.
Moderna’s shares finished the previous trading session at $48.79. The August 5 FDA regulatory decision for mRNA-1010 now represents the company’s next significant catalytic event.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
